Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.40 Consensus Target Price from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $25.40.

Several research analysts have recently commented on KURA shares. CLSA set a $24.00 price objective on Kura Oncology in a research note on Thursday, June 4th. Wedbush upped their price target on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a research note on Monday, June 15th. Finally, Oppenheimer set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th.

Kura Oncology Price Performance

NASDAQ KURA opened at $11.73 on Wednesday. The company has a 50-day moving average price of $11.21 and a 200-day moving average price of $10.05. Kura Oncology has a 52 week low of $7.36 and a 52 week high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.04 billion, a P/E ratio of -3.48 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Equities research analysts anticipate that Kura Oncology will post -3.25 earnings per share for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Brian T. Powl sold 4,345 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $11.89, for a total value of $51,662.05. Following the sale, the insider owned 169,269 shares in the company, valued at $2,012,608.41. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Troy Wilson purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were purchased at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the completion of the purchase, the chief executive officer owned 379,194 shares of the company’s stock, valued at $4,216,637.28. The trade was a 35.82% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 7.60% of the company’s stock.

Institutional Trading of Kura Oncology

A number of large investors have recently made changes to their positions in the business. IFP Advisors Inc lifted its holdings in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares during the period. ProShare Advisors LLC increased its position in shares of Kura Oncology by 10.0% during the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after purchasing an additional 1,692 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Kura Oncology by 49.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after purchasing an additional 1,888 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Kura Oncology by 11.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock valued at $194,000 after buying an additional 2,304 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.